Gene and cell therapy using cell fusion technology
US-11998617-B2 · Jun 4, 2024 · US
Fused cells, e.g. hybridomas
Fused cells, e.g. hybridomas · Cooperative Patent Classification (CPC)
Chemical and metallurgical processes, compounds, and materials.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | C12N5/12 |
| Official title | Fused cells, e.g. hybridomas |
| Display label | Fused cells, e.g. hybridomas |
| Total patents | 174 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is declining.
| Year | Patents |
|---|---|
| 2015 | 17 |
| 2016 | 15 |
| 2017 | 14 |
| 2018 | 18 |
| 2019 | 26 |
| 2020 | 18 |
| 2021 | 17 |
| 2022 | 13 |
| 2023 | 8 |
| 2024 | 16 |
| 2025 | 10 |
| 2026 | 2 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Rep protein as protein antigen for use in diagnostic assays
US-2024018223-A1 · Jan 18, 2024 · US
Antibody for binding to interleukin 4 receptor
US-11866491-B2 · Jan 9, 2024 · US
Antibody that specifically recognizes and binds to reic/dkk-3 protein having active structure and monitoring of cancer treatment using such anti-reic/dkk-3 antibody
US-2018267040-A1 · Sep 20, 2018 · US
Anti-aggrus monoclonal antibody, domain in aggrus which is required for binding to clec-2, and method for screening for aggrus-clec-2 binding inhibitor
US-2018237518-A1 · Aug 23, 2018 · US
Compositions and methods for regulating nk cell activity
US-2018216069-A1 · Aug 2, 2018 · US
Augurin immunoassay
US-10024872-B2 · Jul 17, 2018 · US
Gene and cell therapy using cell fusion technology
US-2018193487-A1 · Jul 12, 2018 · US
Toll-like receptor 3 antagonists
US-2018179294-A1 · Jun 28, 2018 · US
Polynucleotides encoding anti-Notch1 NRR antibody polypeptides
US-10005844-B2 · Jun 26, 2018 · US
Polynucleotides encoding anti-notch1 nrr antibody polypeptides
US-2018112005-A1 · Apr 26, 2018 · US
Methods of reducing clinical symptoms of viral infection by administering a toll-like receptor 3 antagonist
US-9932404-B2 · Apr 3, 2018 · US
Compositions and methods of treating cancer
US-2018085398-A1 · Mar 29, 2018 · US
Compositions and methods of treating acute myeloid leukemia
US-2018078650-A1 · Mar 22, 2018 · US
Antibodies to vla-1
US-2017335000-A1 · Nov 23, 2017 · US
Gdf15 fusion proteins and uses thereof
US-2017327560-A1 · Nov 16, 2017 · US
PROTEIN ASSAY METHOD SPECIFIC TO TRACP-5b (TARTRATE RESISTANT ACID PHOSPHATASE 5b)
US-2017267782-A1 · Sep 21, 2017 · US
Anti-human IgG1 antibody
US-9766251-B2 · Sep 19, 2017 · US
Anti-chondroitin-sulfate-E antibody
US-9745386-B2 · Aug 29, 2017 · US
Polynucleotides encoding anti-notch1 nrr antibody polypeptides
US-2017233486-A1 · Aug 17, 2017 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC C12N5/12?
- CPC C12N5/12 is the Cooperative Patent Classification code for “Fused cells, e.g. hybridomas.”
- How many patents are filed under CPC C12N5/12 (Fused cells, e.g. hybridomas)?
- Our database includes 174 publications tagged with this CPC code.
- Is patent activity under CPC C12N5/12 growing?
- Publication counts under this code: 16 in 2024 vs 10 in 2025 (latest complete years).